Phase 3 Development Program of Novel Selective Estrogen Receptor Modulator (SERM) Represents Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations Financing ...

Pyxis Oncology, Inc. is reallocating its resources to focus on the development of its leading asset, PYX-201, a pioneering antibody-drug conjugate (ADC) showing promising efficacy in treating head and ...

Allakos Inc. announced that its phase 1 trial of AK006 for chronic spontaneous urticaria (CSU) did not show therapeutic efficacy, leading the company to discontinue its development. While AK006 was ...

CEO Dan O'Connell reported that Acumen completed enrollment of its 542-participant Phase 2 ALTITUDE-AD study evaluating Sabirnetug for early Alzheimer’s disease, stating, "We completed enrollment of ...

Work is set to begin on the final phase of Jeffrey Park, more than four decades and 1,600 homes after the Columbus development helped launch the revival of Italian Village. The developer, ...

A Zionsville-based developer is preparing for the next phase of development at a 48-acre residential and commercial project along Michigan Road in Zionsville. Pittman Partners plans to build up to 225 ...

Construction has started on the second phase of the two-phase Somos at McLean Metro, an affordable housing development backed by Amazon.com, SCG Development, a Tysons real estate developer, announced ...

A plan that originated 20 years ago to bring hundreds of new homes to an area located near Rivers Casino Portsmouth and ...

KMBC NINE NEWS IS THE PORT AUTHORITY OF KANSAS CITY HAS APPROVED A NEW PLAN FOR A RIVERFRONT MIXED USE DISTRICT. IT WILL TAKE UP MOST OF THE AREA BETWEEN K STADIUM AND WHERE THE ORIGIN HOTEL IS NOW ...

A rendering of the completed Piazza Alta project. Phase 2 will span two buildings totaling 695 units. Image courtesy of Post Brothers Post Brothers has secured $170 million in construction financing ...

BOTHELL, Wash., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (ATHA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for high unmet medical needs ...